Developer docs
API playgroundTry for free, no card

Search company profiles

ILIAS Biologics

Full company profile

uuid0002c6b

Namestring
ILIAS Biologics
Legal namestring
ILIAS Biologics Inc.
Websiteurl
iliasbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

ILIAS Biologics is a clinical-stage South Korean biotechnology company founded in 2015, headquartered in Daejeon with a US operating subsidiary (ILIAS Therapeutics, Inc.) in Gilroy, California. The company specializes in engineered exosomes for intracellular delivery of large protein therapeutics, built around three proprietary platforms: EXPLOR® (an optogenetically controlled, optically reversible protein-protein interaction system that loads functionally active cargo proteins — including intracellular antibodies, organelle-targeted proteins, and gene-editing proteins — into exosomes in free-form), Exo-Target® (surface-engineered exosomes that improve active tissue targeting and enable cross-barrier protein delivery, including blood-brain barrier penetration), and Pure-Exo® (a GMP-compliant manufacturing process featuring Master Cell Bank development, bioreactor-based suspension culture, sequential ultrafiltration and chromatography purification, and GMP formulation/filling).

The company's lead clinical asset, ILB-202, is an exosome loaded with super-repressor IκB (srIκB) designed to inhibit the intracellular NF-κB signaling pathway for inflammatory and autoimmune indications including acute kidney injury, sepsis, rheumatoid arthritis, biliary atresia, and alcohol-associated liver disease. ILB-202 completed a Phase 1 clinical trial in Australia in 2023–2024, demonstrating safety, tolerability, and selective NF-κB pathway modulation, with results published in the Journal of Extracellular Vesicles in September 2025. Pipeline expansion extends into oncology (via the June 2022 JW Pharmaceutical collaboration on small-molecule anti-cancer exosomes), CNS diseases, and women's health through the July 2025 IL WHT subsidiary (focused on endometriosis and chorioamnionitis, backed by the 2025 KDDF National New Drug Development Project).

The business model is a hybrid of platform licensing and co-development with pharmaceutical partners, supplemented by a contract research service (EV2aluation, launched October 2022) and an open-innovation collaboration platform (VOICE). Revenue is pre-commercial, with no approved products. The company has raised approximately $37M+ in disclosed equity across Series A ($17M, 2018), Series B ($20M, 2020), and Series C (undisclosed, 2022), supported by non-dilutive government and grant funding (NIH R21, KDDF, Ministry of Health and Welfare, KBIOHealth, MFDS Bio Challenger Program). Patents are granted across the US, Korea, Japan, China, Australia, Canada, and Israel.

Short descriptiontext

ILIAS Biologics is a clinical-stage South Korean biotech developing engineered exosome therapeutics using its proprietary EXPLOR®, Exo-Target®, and Pure-Exo® platforms. Its lead asset ILB-202 targets inflammatory diseases via intracellular NF-κB inhibition, with pipeline expansion into oncology, CNS, and women's health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome therapeutics, intracellular drug delivery, engineered exosome platforms, protein therapeutics delivery, biopharmaceutical R&D
Industry3 codes
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Exosome Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Development and commercialization of exosome-based therapeutics through proprietary platform technologies. Lead program ILB-202 is in clinical development for inflammatory diseases. Revenue expected through product sales upon regulatory approval.

iliasbio.com
2Platform Licensing and Co-development
TypeLicensing Royalties
Description

Platform-based research and option agreements for technology licensing to pharmaceutical partners. In-house asset licensing with robust development of in-house pipelines. Co-development of exosome-based therapeutics through research collaboration and option agreements with novel therapeutic cargo and tissue/organ targeting capabilities.

iliasbio.com
3Contract Research Services
TypeProfessional Services
Description

EV2aluation service offered starting October 2022, providing exosome evaluation services to external partners.

iliasbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IL WHT (ILIAS Women's Health Therapeutics)
Description

Dedicated subsidiary focused on developing innovative exosome-based treatments specifically targeting obstetric and gynecological disorders.

iliasbio.com
Core offering1 text field

ILIAS Biologics develops engineered exosome-based therapeutics through proprietary platform technologies (EXPLOR®, Exo-Target®, Pure-Exo®) that enable intracellular delivery of large protein therapeutics such as antibodies. The lead clinical candidate ILB-202 delivers super-repressor IκB to target NF-κB signaling for inflammatory diseases, with additional pipeline programs in oncology and CNS indications, supplemented by the EV2aluation exosome characterization service.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 clinical trial demonstrated ILB-202 was safe and well tolerated with no discontinuation, no serious adverse events, and no adverse events of special interest
+2 more records
Product overview1 text field

ILIAS Biologics is a global biopharmaceutical company developing engineered exosome-based therapeutics through its proprietary platform technologies: EXPLOR® for intracellular protein loading, Exo-Target® for targeted delivery, and Pure-Exo® for scalable manufacturing. The company's lead product is ILB-202, an exosome containing super-repressor IκB for treating inflammatory diseases. They also offer the EV2aluation service for exosome characterization and maintain VOICE, an open innovation research collaboration platform.

Product and service1 record
1ILB-202
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Daejeon Technopark
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Trilateral MOU with Daejeon Metropolitan Government and California-based biotech media firm BioCentury to establish channel connecting local biotech companies with global investors and pharmaceutical partners. Includes investor relations pitching session.

koreaherald.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Selected for 2025 Second National New Drug Development Project for exosome-based endometriosis treatment. KDDF provides research funds over two years for non-clinical development and clinical trial plan approval (IND).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Selected for 2025 Advanced Medical Industry Leading Infrastructure Demonstration Support Program funded by Ministry of Health and Welfare. KBIOHealth supports GMP-compliant production and quality validation of ILB-202, including manufacturing and quality evaluation of Working Cell Bank, GMP process development, and quality verification.

4Ministry of Food and Drug Safety (MFDS) - Bio Challenger Program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Selected for 2025 Bio Challenger program led by MFDS. Program provides tailored regulatory and development support from preclinical to clinical trial and market approval stages, including scientific consultation, regulatory guidance, and clinical design support.

iliasbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-11
Description

Selected as winner of 2022 KDDF National New Drug Development Project to develop exosome-based IBD (Inflammatory Bowel Disease) treatment. KDDF provides research funding and support for the project.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-14
Description

Collaborative research agreement to develop an exosome-based small molecular anti-cancer treatment. ILIAS contributes its exosome platform technology while JW Pharmaceutical contributes small molecular anti-cancer compounds and drug development expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-27
Description

MOU for joint research to develop new biomedicine candidates using exosomes as next-generation drug delivery systems. Combines ILIAS's versatile exosome platform technologies with HK inno.N's extensive new drug development know-how.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing exosome-based therapeutics (CAP-1002, CAP-2003) for Duchenne muscular dystrophy and inflammatory diseases. Directly comparable as a clinical-stage exosome therapeutics company targeting inflammatory indications with engineered extracellular vesicles.

TypeDirect peer
Description

UK-based developer of engineered exosomes for intracellular delivery of nucleic acids and proteins, with focus on CNS and rare diseases. Closest direct competitor with proprietary exosome engineering platform comparable to ILIAS's EXPLOR® and Exo-Target® technologies.

3Codiak BioSciences
TypeDirect peer
Description

Pioneer in engineered exosome therapeutics (exoIL-12, exoSTING) for oncology. Most advanced exosome platform historically with clinical-stage programs. Provides key reference for exosome therapeutic clinical development and regulatory pathway despite Codiak's 2023 restructuring.

TypeRegional player
Description

South Korean exosome company developing regenerative aesthetics and therapeutics. Regional peer sharing Korean biotech ecosystem, government support programs, and exosome manufacturing infrastructure. Direct overlap in inflammation/regenerative applications.

TypeEmerging player
Description

Clinical-stage RNA medicines company with proprietary lipid nanoparticle delivery platform (LUNAR®). Comparable as a delivery-platform biotech with intracellular delivery focus, though using LNP technology vs. ILIAS's exosome approach. Validates market for advanced intracellular delivery therapeutics.

6Mantra Bio
TypeEmerging player
Description

Developer of exosome-based therapeutics for targeted drug delivery, including CNS applications. Emerging peer with overlapping focus on engineered exosomes for hard-to-treat diseases and blood-brain barrier penetration.

TypeBroad incumbent
Description

Large biotech holding company with multiple platform technologies and inflammation/autoimmune assets. Comparable as a publicly-traded company developing inflammation therapeutics that could be a potential acquirer or licensing partner for ILB-202.

TypeBroad incumbent
Description

Established life sciences tools and reagents company including exosome research products (ExoDx prostate test, exosome isolation kits). Provides adjacent ecosystem support and reference for exosome-related commercialization, though focused on tools rather than therapeutics.

TypeOthers
Description

South Korean pharmaceutical company and existing ILIAS Biologics partner for exosome-based anti-cancer treatment development (2022 collaboration). Strategic partner and potential acquirer with established small-molecule oncology pipeline seeking biologics platform extension.

TypeDirect peer
Description

Korean-based clinical-stage biotech developing intracellular protein delivery using cell-penetrating technology for inflammatory and CNS indications. Closest Korean peer with comparable intracellular delivery focus and inflammatory disease pipeline (similar to ILB-202's NF-κB approach).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ILIAS Biologics

Exosome Therapeuticsiliasbio.com

ILIAS Biologics is a clinical-stage South Korean biotech developing engineered exosome therapeutics using its proprietary EXPLOR®, Exo-Target®, and Pure-Exo® platforms. Its lead asset ILB-202 targets inflammatory diseases via intracellular NF-κB inhibition, with pipeline expansion into oncology, CNS, and women's health.

What ILIAS Biologics does

ILIAS Biologics is a clinical-stage South Korean biotechnology company founded in 2015, headquartered in Daejeon with a US operating subsidiary (ILIAS Therapeutics, Inc.) in Gilroy, California. The company specializes in engineered exosomes for intracellular delivery of large protein therapeutics, built around three proprietary platforms: EXPLOR® (an optogenetically controlled, optically reversible protein-protein interaction system that loads functionally active cargo proteins — including intracellular antibodies, organelle-targeted proteins, and gene-editing proteins — into exosomes in free-form), Exo-Target® (surface-engineered exosomes that improve active tissue targeting and enable cross-barrier protein delivery, including blood-brain barrier penetration), and Pure-Exo® (a GMP-compliant manufacturing process featuring Master Cell Bank development, bioreactor-based suspension culture, sequential ultrafiltration and chromatography purification, and GMP formulation/filling).

The company's lead clinical asset, ILB-202, is an exosome loaded with super-repressor IκB (srIκB) designed to inhibit the intracellular NF-κB signaling pathway for inflammatory and autoimmune indications including acute kidney injury, sepsis, rheumatoid arthritis, biliary atresia, and alcohol-associated liver disease. ILB-202 completed a Phase 1 clinical trial in Australia in 2023–2024, demonstrating safety, tolerability, and selective NF-κB pathway modulation, with results published in the Journal of Extracellular Vesicles in September 2025. Pipeline expansion extends into oncology (via the June 2022 JW Pharmaceutical collaboration on small-molecule anti-cancer exosomes), CNS diseases, and women's health through the July 2025 IL WHT subsidiary (focused on endometriosis and chorioamnionitis, backed by the 2025 KDDF National New Drug Development Project).

The business model is a hybrid of platform licensing and co-development with pharmaceutical partners, supplemented by a contract research service (EV2aluation, launched October 2022) and an open-innovation collaboration platform (VOICE). Revenue is pre-commercial, with no approved products. The company has raised approximately $37M+ in disclosed equity across Series A ($17M, 2018), Series B ($20M, 2020), and Series C (undisclosed, 2022), supported by non-dilutive government and grant funding (NIH R21, KDDF, Ministry of Health and Welfare, KBIOHealth, MFDS Bio Challenger Program). Patents are granted across the US, Korea, Japan, China, Australia, Canada, and Israel.

ILIAS Biologics firmographics

Firmographics
Name
ILIAS Biologics
Legal name
ILIAS Biologics Inc.
Website
https://iliasbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ILIAS Biologics is a clinical-stage South Korean biotech developing engineered exosome therapeutics using its proprietary EXPLOR®, Exo-Target®, and Pure-Exo® platforms. Its lead asset ILB-202 targets inflammatory diseases via intracellular NF-κB inhibition, with pipeline expansion into oncology, CNS, and women's health.
Ownership category
akta.pro rank

ILIAS Biologics industry classification

Industry
Product category
Exosome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Exosome therapeutics
  • Intracellular drug delivery
  • Engineered exosome platforms
  • Protein therapeutics delivery
  • Biopharmaceutical R&D

Where ILIAS Biologics is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

ILIAS Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Development and Commercialization: Development and commercialization of exosome-based therapeutics through proprietary platform technologies. Lead program ILB-202 is in clinical development for inflammatory diseases. Revenue expected through product sales upon regulatory approval.
  2. Platform Licensing and Co-development: Platform-based research and option agreements for technology licensing to pharmaceutical partners. In-house asset licensing with robust development of in-house pipelines. Co-development of exosome-based therapeutics through research collaboration and option agreements with novel therapeutic cargo and tissue/organ targeting capabilities.
  3. Contract Research Services: EV2aluation service offered starting October 2022, providing exosome evaluation services to external partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

ILIAS Biologics product offering

Product offering

Core offering

ILIAS Biologics develops engineered exosome-based therapeutics through proprietary platform technologies (EXPLOR®, Exo-Target®, Pure-Exo®) that enable intracellular delivery of large protein therapeutics such as antibodies. The lead clinical candidate ILB-202 delivers super-repressor IκB to target NF-κB signaling for inflammatory diseases, with additional pipeline programs in oncology and CNS indications, supplemented by the EV2aluation exosome characterization service.

Product overview

ILIAS Biologics is a global biopharmaceutical company developing engineered exosome-based therapeutics through its proprietary platform technologies: EXPLOR® for intracellular protein loading, Exo-Target® for targeted delivery, and Pure-Exo® for scalable manufacturing. The company's lead product is ILB-202, an exosome containing super-repressor IκB for treating inflammatory diseases. They also offer the EV2aluation service for exosome characterization and maintain VOICE, an open innovation research collaboration platform.

Differentiator

Problem solved

Functional benefit

Brands

  • IL WHT (ILIAS Women's Health Therapeutics): Dedicated subsidiary focused on developing innovative exosome-based treatments specifically targeting obstetric and gynecological disorders.

Products and services

  • ILB-202

Quantifiable outcome

  • Phase 1 clinical trial demonstrated ILB-202 was safe and well tolerated with no discontinuation, no serious adverse events, and no adverse events of special interest
  • +2 more outcomes

Companies that use ILIAS Biologics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

ILIAS Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ILIAS Biologics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Daejeon TechnoparkminorStrategic or Co-development Partner · 11 March 2026Trilateral MOU with Daejeon Metropolitan Government and California-based biotech media firm BioCentury to establish channel connecting local biotech companies with global investors and pharmaceutical partners. Includes investor relations pitching session.
  • Korea Drug Development Fund (KDDF)coreStrategic or Co-development Partner · 18 December 2025Selected for 2025 Second National New Drug Development Project for exosome-based endometriosis treatment. KDDF provides research funds over two years for non-clinical development and clinical trial plan approval (IND).
  • KBIOHealth (Osong Medical Innovation Foundation)coreStrategic or Co-development Partner · 3 September 2025Selected for 2025 Advanced Medical Industry Leading Infrastructure Demonstration Support Program funded by Ministry of Health and Welfare. KBIOHealth supports GMP-compliant production and quality validation of ILB-202, including manufacturing and quality evaluation of Working Cell Bank, GMP process development, and quality verification.
  • Ministry of Food and Drug Safety (MFDS) - Bio Challenger ProgramcoreStrategic or Co-development Partner · 2 September 2025Selected for 2025 Bio Challenger program led by MFDS. Program provides tailored regulatory and development support from preclinical to clinical trial and market approval stages, including scientific consultation, regulatory guidance, and clinical design support.
  • Korea Drug Development Fund (KDDF)coreStrategic or Co-development Partner · 11 August 2022Selected as winner of 2022 KDDF National New Drug Development Project to develop exosome-based IBD (Inflammatory Bowel Disease) treatment. KDDF provides research funding and support for the project.
  • JW PharmaceuticalcoreStrategic or Co-development Partner · 14 June 2022Collaborative research agreement to develop an exosome-based small molecular anti-cancer treatment. ILIAS contributes its exosome platform technology while JW Pharmaceutical contributes small molecular anti-cancer compounds and drug development expertise.
  • HK inno.NcoreStrategic or Co-development Partner · 27 May 2022MOU for joint research to develop new biomedicine candidates using exosomes as next-generation drug delivery systems. Combines ILIAS's versatile exosome platform technologies with HK inno.N's extensive new drug development know-how.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

ILIAS Biologics competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (CAP-1002, CAP-2003) for Duchenne muscular dystrophy and inflammatory diseases. Directly comparable as a clinical-stage exosome therapeutics company targeting inflammatory indications with engineered extracellular vesicles.
  • Evox Therapeutics: UK-based developer of engineered exosomes for intracellular delivery of nucleic acids and proteins, with focus on CNS and rare diseases. Closest direct competitor with proprietary exosome engineering platform comparable to ILIAS's EXPLOR® and Exo-Target® technologies.
  • Codiak BioSciences: Pioneer in engineered exosome therapeutics (exoIL-12, exoSTING) for oncology. Most advanced exosome platform historically with clinical-stage programs. Provides key reference for exosome therapeutic clinical development and regulatory pathway despite Codiak's 2023 restructuring.
  • Cellivery Therapeutics: Korean-based clinical-stage biotech developing intracellular protein delivery using cell-penetrating technology for inflammatory and CNS indications. Closest Korean peer with comparable intracellular delivery focus and inflammatory disease pipeline (similar to ILB-202's NF-κB approach).

Regional players

  • ExoCoBio: South Korean exosome company developing regenerative aesthetics and therapeutics. Regional peer sharing Korean biotech ecosystem, government support programs, and exosome manufacturing infrastructure. Direct overlap in inflammation/regenerative applications.

Emerging players

  • Arcturus Therapeutics: Clinical-stage RNA medicines company with proprietary lipid nanoparticle delivery platform (LUNAR®). Comparable as a delivery-platform biotech with intracellular delivery focus, though using LNP technology vs. ILIAS's exosome approach. Validates market for advanced intracellular delivery therapeutics.
  • Mantra Bio: Developer of exosome-based therapeutics for targeted drug delivery, including CNS applications. Emerging peer with overlapping focus on engineered exosomes for hard-to-treat diseases and blood-brain barrier penetration.

Broad incumbents

  • Roivant Sciences: Large biotech holding company with multiple platform technologies and inflammation/autoimmune assets. Comparable as a publicly-traded company developing inflammation therapeutics that could be a potential acquirer or licensing partner for ILB-202.
  • Bio-Techne: Established life sciences tools and reagents company including exosome research products (ExoDx prostate test, exosome isolation kits). Provides adjacent ecosystem support and reference for exosome-related commercialization, though focused on tools rather than therapeutics.

Others

  • JW Pharmaceutical: South Korean pharmaceutical company and existing ILIAS Biologics partner for exosome-based anti-cancer treatment development (2022 collaboration). Strategic partner and potential acquirer with established small-molecule oncology pipeline seeking biologics platform extension.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ILIAS Biologics social profiles

Digital presence

ILIAS Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ILIAS Biologics leadership team

Management profile

Number of profiles

Profiles6 records

ILIAS Biologics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ILIAS Biologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ILIAS Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ILIAS Biologics

What does ILIAS Biologics do?

ILIAS Biologics develops engineered exosome-based therapeutics through proprietary platform technologies (EXPLOR®, Exo-Target®, Pure-Exo®) that enable intracellular delivery of large protein therapeutics such as antibodies. The lead clinical candidate ILB-202 delivers super-repressor IκB to target NF-κB signaling for inflammatory diseases, with additional pipeline programs in oncology and CNS indications, supplemented by the EV2aluation exosome characterization service.

Is ILIAS Biologics a public or private company?

ILIAS Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was ILIAS Biologics founded?

ILIAS Biologics was founded in 2015. It employs 11 to 50 people.

Where is ILIAS Biologics based?

ILIAS Biologics is headquartered in Daejeon, South Korea, in the Asia region.

How does ILIAS Biologics make money?

Three revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are platform Licensing and Co-development and contract Research Services.

Who are ILIAS Biologics's main competitors?

Direct peers on record are Capricor Therapeutics, Evox Therapeutics, Codiak BioSciences and Cellivery Therapeutics. ExoCoBio is listed as a regional player. Emerging players are Arcturus Therapeutics and Mantra Bio. Broad incumbents are Roivant Sciences and Bio-Techne. JW Pharmaceutical is listed as an others.

Does ILIAS Biologics have an API?

No public API is recorded for ILIAS Biologics.

What industry is ILIAS Biologics in?

ILIAS Biologics's product category is Exosome Therapeutics. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyInside exosomes: Nature’s drug carriersExosomes are being developed as drug carriers to overcome delivery hurdles, with companies like Evox Therapeutics and Aruna Bio advancing CNS and stroke therapies. Evox targets Huntington's disease with a Phase 1/2 trial planned for 2027, while Aruna Bio's AB126 reached Phase 1b. The field is expected to see IP consolidation and manufacturability breakthroughs over the next 5–10 years.Labiotech.euExtracellular vesicles: a growing pipeline still searching for validationExtracellular vesicle therapeutics have generated over 100 clinical studies but no approved drug, with technical and regulatory barriers persisting. The field is split into three models: native EVs for repair, engineered EVs as delivery vehicles, and EV-based vaccines, with the strongest signals from defined uses.Delveinsight5 Exosome Therapies in the Clinical PipelineDelveInsight has published an industry overview highlighting five exosome-based therapies currently in clinical development, including Deramiocel (Capricor Therapeutics/Nippon Shinyaku), ExoFlo (Direct Biologics), AGLE-102 (Aegle Therapeutics), BRE-AD01 (Brexogen), and ILB-202 (ILIAS Biologics). Capricor's Deramiocel for Duchenne muscular dystrophy has reached a critical milestone with an FDA PDUFA target date of August 22, 2026, following resumption of its Biologics License Application review. The article also profiles emerging developers such as Aruna Bio, NurExone Biologic, and VivaZome Therapeutics advancing exosome candidates for neurological conditions, while noting that no exosome-based therapy has yet received FDA approval.PR NewswireILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injuryILIAS Biologics Inc. demonstrated the therapeutic efficacy of its anti-inflammatory exosomes in treating ischemia-reperfusion-induced acute kidney injury through a study conducted with Yonsei University. The research, published in Kidney International, showed that the treatment significantly lowered AKI-related biomarkers and reduced inflammation in preclinical mouse models. Based on these results, ILIAS plans to submit an application for a first-in-human Phase 1 clinical trial by the end of 2021.FierceBiotechSouth Korean exosome biotech Ilias Biologics nabs $20M B roundIlias Biologics raised $20.6 million in a funding round to advance its exosome-based therapeutics. The company plans to submit an IND for a first-in-human test by the second half of 2021, targeting an undisclosed acute inflammatory disease. It is also in discussions with multiple pharmaceutical companies for R&D collaborations.